The presence of prostate cancer at biopsy is predicted by a number of genetic variants (pages 1139–1146)
Aniruddh Kashyap, Wojciech Kluźniak, Dominika Wokołorczyk, Adam Gołąb, Andrzej Sikorski, Marcin Słojewski, Bartłomiej Gliniewicz, Jerzy Świtała, Tomasz Borkowski, Andrzej Borkowski, Andrzej Antczak, Łukasz Wojnar, Jacek Przybyła, Marek Sosnowski, Bartosz Małkiewicz, Romuald Zdrojowy, Paulina Sikorska-Radek, Józef Matych, Jacek Wilkosz, Waldemar Różański, Jacek Kiś, Krzysztof Bar, Piotr Bryniarski, Andrzej Paradysz, Konrad Jersak, Jerzy Niemirowicz, Piotr Słupski, Piotr Jarzemski, Michał Skrzypczyk, Jakub Dobruch, Paweł Domagała, Krzysztof Piotrowski, Anna Jakubowska, Jacek Gronwald, Tomasz Huzarski, Tomasz Byrski, Tadeusz Dębniak, Bohdan Górski, Bartłomiej Masojć, Thierry van de Wetering, Janusz Menkiszak, Mohammad R. Akbari, Jan Lubiński, Steven A. Narod, Cezary Cybulski and the Polish Hereditary Prostate Cancer Consortium
Article first published online: 16 SEP 2013 | DOI: 10.1002/ijc.28447
While more than 70 single nucleotide polymorphisms (SNPs) are associated with an increased risk of prostate cancer, whether SNPs can predict the presence of prostate cancer at biopsy remains uncertain. In this multi-center study, 4,548 Polish men were biopsied and genotyped for 11 different SNPs, five of which were positively associated with prostate cancer. The cancer detection rate was 63 percent for men who carried seven or more risk alleles, though this high-risk group represents only about one percent of prostate cancers. The findings do not support SNPs as adjuncts to clinical screening.